<DOC>
	<DOCNO>NCT01447758</DOCNO>
	<brief_summary>The purpose Phase Ib study investigate safety , tolerability pharmacokinetics LEO 29102 2,5 mg/g cream treat atopic dermatitis ( AD ) lesions 10 100 % body surface area ( BSA ) twice daily ( BID ) 7 day ( Cohorts I , II , III ) 10 % 50 % BSA ( bid ) 6 week ( Cohort IV ) . This trial perform four cohort . Cohort I , II III include patient large BSA increase one cohort next . After cohort ( Cohort I , II ) blind evaluation safety tolerability data assess whether stepwise increase percentage `` treat BSA '' justify . Cohort IV start dose finalisation Cohort II submission data Cohort I II national authority IEC review .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics LEO 29102 Cream Atopic Dermatitis .</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Clinical diagnosis AD define accord Hanifin Rajka . 2 . Investigator Global Assessment score mild ( 2 ) severe ( 4 ) AD . 3 . At screen , AD lesion amenable treatment involve 10 % &lt; 25 % ( Cohort I ) , 25 % &lt; 50 % ( Cohort II ) , 50 % 100 % ( Cohort III ) 10 % &lt; 50 % ( Cohort IV ) total BSA . 4 . On Day 1 , AD lesion amenable treatment involve 10 % &lt; 28 % ( Cohort I ) , 25 % &lt; 55 % ( Cohort II ) , 50 % 100 % ( Cohort III ) 10 % &lt; 55 % ( Cohort IV ) total BSA . 5 . Adult male female subject , age 18 65 year , inclusive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>